If you turn the chart upside down then its doesn't look so bad. I'm taking a new approach like the longs & only mentioning positives. If Otrexup had another 1K weekly scripts then they would be operating in the positive. This is easy.
The reason is that foreign countries are not going to pay for an expensive injector when a basic pre-filled syringe works just as good. The need for an injector due to limited hand dexterity is BS.
I was just giving you some info on Orbimed. I've stated my profession any number of times. Nurse Anesthetist, I was a CPA before changing professions so I know a little about everything & an expert on nothing.
You don't have a clue. The only thing that matters to insurers is price. If Otrexup is cheaper then that will be the preferred injector & if Rasuvo is cheaper then the same holds true.
Orbimed had 6 milion shares in 2010 when it was AIS. They sold half in the 2nd qtr 2013 & the rest in 2nd qtr 2014.
ATRS believes additional competitors will help sales. I imagine Medac will use that statement against them in court. Why is ATRS trying to prevent the entry of Rasuvo onto the market if its going to help sales?
Will ATRS get another beat down on the launch news? I was originally thinking ATRS would get a pop if the launch was delayed in the courts but now it looks like that's not going to happen.
Keep drinking the coolaid they have plenty for everyone. Wotten hinted at any number of deals which never came true.
Thanks for the props. There were a few posters who were happy to post that I was getting killed when it initially traded down over 10%.
Td, if that's true then ATRS is run by a bunch of idiots that don't understand the market. How can you launch a drug & not know that a huge percentage of your scripts won't be filled due to your pricing strategy?
You do know a private company is also running Phase III trials & they may actually be ahead of CPRX on their NDA filing timeline. Adam Feuerstein has written about this extensively.
I've previously stated that they needed a higher new subscription rate or else the peak was going to come quickly. New subscribers = those stopping the drug